Arun Balakumaran

Arun Balakumaran has extensive experience in the medical field. Arun is currently the Chief Medical Officer at Replay since 2023. Prior to this, they held the same role at Allogene Therapeutics from 2022 to 2023. At Allogene Therapeutics, they also served as the Senior Vice President and Head of Clinical Development from 2018 to 2022. Before joining Allogene Therapeutics, Arun worked at Merck as a Distinguished Scientist and Product Development Leader for Hematology from 2014 to 2018. Arun also worked at Amgen, where they were the North American Medical Lead from 2013 to 2014 and the Medical Director of Clinical Development from 2010 to 2013. Arun began their career at the National Institutes of Health, where they held various roles including Principal Investigator/Staff Clinician from 2007 to 2010 and Clinical and Post-doctoral Research Fellowship from 2004 to 2007.

Arun Balakumaran has pursued a Master's degree in Health/Health Care Administration/Management from Harvard University. Additionally, Arun has also been associated with The University of Texas Medical Branch, although no further details regarding degree or field of study are provided.